Related Experiment Video
Updated: Oct 8, 2025
08:43
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
Published on: January 14, 2020
11.5K
Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma
Benjamin Mwesige1,2, Mi Rim Lee1,2, Yu-Sun Lee2,3
1Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.
Anticancer Research
|December 31, 2021
Summary
Researchers developed new preclinical models for invasive papillary cholangio-carcinoma (IPC), a rare bile duct cancer. These models will help understand IPC causes and test new treatments.
Area of Science:
- Oncology
- Translational Research
- Cancer Models
Background:
- Invasive papillary cholangio-carcinoma (IPC) is a rare subtype of extrahepatic cholangiocarcinoma.
- Its etiology and characteristics are poorly understood due to a lack of suitable models.
Purpose of the Study:
- To establish novel preclinical models for invasive papillary cholangio-carcinoma.
- To facilitate translational research for IPC.
Main Methods:
- A patient-derived xenograft (PDX) model was created from IPC patient tumors.
- A cell line, National Cancer Center human IPC (NCChIPC), was established from the PDX.
- Immunohistochemistry and RNA-sequencing confirmed model fidelity to original tumors.
Main Results:
- The NCChIPC xenograft model retained key histopathological features and biomarker expression (CK19, MUC1, MUC5AC).
- Transcriptome analysis demonstrated high correlation between patient tumors and the preclinical model.
- Anticancer drug responses were evaluated in the NCChIPC PDX model.
Conclusions:
- Novel preclinical models for IPC have been successfully established.
- These models will aid in elucidating IPC etiology.
- The models will accelerate translational research and drug development for IPC.
